Single-Use Assemblies Market Size Worth $6.5 billion by 2027

Posted December 14, 2022 by Healthcare101

The Global Single Use Assemblies Market size is projected to reach $6.5 billion by 2027, at a CAGR of 18.8% during the forecast period.
The Global Single Use Assemblies Market size is projected to reach $6.5 billion by 2027, at a CAGR of 18.8% during the forecast period. The growth of the single use assemblies market is largely driven by advantages of single-use assemblies over traditional stainless steel equipment such as quick implementation from small to large scale production, cost effective solution. Additionally, growing adoption of single-use assemblies in research activities, coupled with increased investments in biopharmaceutical R&D activities is upsurging the market growth across the globe.

Key Players:
Thermo Fisher Scientific, Inc. (US), Sartorius Stedim Biotech (France), Danaher Corporation (US), Merck KGaA (Germany), Avantor, Inc (US), Parker-Hannifin Corporation (US), Saint-Gobain (France), Repligen Corporation (US), Corning Incorporated (US), Entegris, Inc. (US), Meissner Filtration Products (US), NewAge Industries (US), Antylia Scientific (US), Lonza (Basel), Romynox B.V (Hague), FlexBiosys, Inc. (US), Keofitt A/S (Denmark), Intellitech, Inc. (US), Dover Corporation (US), Foxx Life Sciences (US), TSE Industries Inc. (US), Fujimori Kogyo Co. Ltd (Japan), Michelin (France), Cellexus International Ltd (UK), and Fluid Flow Products (US).

Download PDF Brochure:

Single Use Assemblies Market Global Dynamics
Drivers: Increasing Biopharmaceutical R&D is projecting the industry growth
Key players operating in the global single use assemblies market are increasingly focused on developing and commercializing technologically advanced single-use assemblies products that offer streamlined workflows, ease of operability, and rapid implementation. As single-use assemblies contributes largely to small and large scale biopharmaceutical manufacturing, increasing investments in biopharmaceutical R&D for product development is attributed to high market growth of single-use assemblies. Advantages of single-use assemblies like low risk of product cross-contamination, elimination of additional sterilization process are driving the market growth of single-use assemblies. For instance, the 15 largest pharmaceutical companies invested a record USD 133 billion in 2021 in R&D expenditure.

Restraints: Issues related to extractables and leachables
Most end users, such as large research facilities, and pharmaceutical companies, require many single-use assemblies to simultaneously carry out multiple research studies and production process. This studies and process are carried out at high temperature and environmental conditions. Single-use assemblies made of polymers and plastics containing various preservatives which are likely to degrade in form of extractables and leachables in small amount. This posseses the risk of cross contamination of the material. Thus, extractables and leachables are major concerns limiting the market growth of single-use assemblies.

Opportunities: Emerging Countries
Owing to its advantages, the adoption of single-use assemblies has increased significantly during the last decade. In addition to the supportive regulatory environment and cost advantages in emerging countries like China, India and South Korea, many pharmaceuticals and biopharmaceutical companies are expected to expand their single-use manufacturing plants to make this countries hub for bioprocess outsourcing. This is also supported by the increasing number of investments from key players of the market into the developing countries. For instance, Cytiva in collaboration with Wego Pharmaceutical expanded its manufacturing capacity in china to strengthen its supply chain in APAC region.

Request Sample Pages:

Biopharmaceuticals & Pharmaceutical companies held a dominant share in end user segment in Single use assemblies market
Based on end user, the single-use assemblies market is segmented into biopharmaceuticals and pharmaceutical companies, contract research organizations & contract manufacturing organizations, and academic & research institutes. The biopharmaceuticals and pharmaceutical companies segment accounted for the largest market share in 2021. Higher adoption of standard solutions are mainly due to flexibility of their use with pre-qualified components of different assemblies, increased cost-efficiency and rapid implementation of a production plan from small scale to large scale. These are the factors attributed to increasing demand for single-use assemblies products in this end user segment. Additionally, growing investments by pharmaceutical companies in research activity further support market growth.

North America accounted for largest share in single use assemblies market in 2021
Geographically, the single use assemblies market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America held dominant share followed by Europe. North America held a dominant share owing to various factor such as increased biologics and biosimilar production in region followed by the huge number of key market players with well established infrastructure for large scale manufacturing. However, the APAC market is expected to grow at higher CAGR during the forecasts period. Factors such as the presence of a favourable business environment, increased capital investments in biopharmaceutical R&D and life sciences research are accountable for growth of the single use assemblies market in the region.

Recent Developments:
• In April 2022, Merck KGaA (Germany), planed to invest around USD 110 million for expanding the existing Wuxi production site (China) to substantially expand biopharma single-use assemblies and custom design capabilities. With this expansion, Merck will broaden its geographic footprint and strengthen its supply chain in China and the Asia-Pacific region.
• September 2021, Cytiva planned to triple single-use component production in China through Wego Pharmaceutical Co.’s Weihai, China. 11 manufacturing lines are planned to be launched by end of Q3 2022.

Inquiry Before Buying:

About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: 1-888-600-6441
Email: [email protected]

Related Report:
Cell Culture Media Market
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Healthcare101
Country United States
Categories Health , Medical , Research
Last Updated December 14, 2022